Leap Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Leap Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Leap Therapeutics Inc Strategy Report
- Understand Leap Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. FL-301, a monoclonal antibody that targets Claudin18.2, is being tested in patients with gastric and pancreatic cancer. The company has an agreement with BeiGene Ltd for development rights and commercialization of DKN-01 in Australia, Asia (excluding Japan) and New Zealand. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Leap Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
DKN-01 - Gastroesophageal Cancer/ Prostate Cancer / Gynecologic Cancer |
FL-301 (NBL-105) - Gastric/ Pancreatic |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In March, the company entered into an agreement with BeiGene for trial, a randomized controlled trial of DKN-01 in combination with BeiGene's anti-PD-1 antibody, tislelizumab, and chemotherapy in first-line gastric cancer patients, as a clinical collaboration with BeiGene supplying tislelizumab. |
2023 | Contracts/Agreements | In January, the company entered into an agreement to acquire Flame Biosciences, Inc. |
2022 | Contracts/Agreements | In January, the company entered into an agreement with Leica Biosystems to develop companion diagnostic tests to detect Dickkopf-related protein 1 (DKK1) for cancer therapy. |
Competitor Comparison
Key Parameters | Leap Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Bristol-Myers Squibb Co | Amgen Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Cambridge | Kenilworth | New York | Princeton | Thousand Oaks |
State/Province | Massachusetts | New Jersey | New York | New Jersey | California |
No. of Employees | 54 | 72,000 | 88,000 | 34,100 | 26,700 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Christopher K. Mirabelli, Ph.D. | Chairman | Executive Board | 2016 | 68 |
Douglas E. Onsi | President; Chief Executive Officer; Director | Executive Board | 2020 | 54 |
Augustine Lawlor | Chief Operating Officer | Senior Management | 2016 | 66 |
Cyndi Sirard, M.D. | Chief Medical Officer | Senior Management | 2020 | 53 |
Jason Baum, Ph.D. | Chief Scientific Officer | Senior Management | 2023 | 44 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer